Investors

Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.

Latest results

Portfolio metrics

35+
Approved products
14
Development-stage therapies
15
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration

Financial metrics

$3.0bn
Portfolio Receipts
(2023)
$2.8bn
Adjusted EBITDA
(2023)
$2.0bn
Average annual capital deployed (2018-2023)
$4.0bn
Announced value of transactions (2023)

Corporate presentation

SEC filings

Filing Date Form View
Loading…
All Filings

Latest releases

Royalty Pharma Announces Dividend Increase

NEW YORK, NY, January 19, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend.

Stay up to date

Subscribe to Royalty Pharma news and alerts

Subscribe